{
    "clinical_study": {
        "@rank": "73756", 
        "arm_group": [
            {
                "arm_group_label": "Berinert, then CSL830", 
                "arm_group_type": "Experimental", 
                "description": "A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU."
            }, 
            {
                "arm_group_label": "CSL830, then Berinert", 
                "arm_group_type": "Experimental", 
                "description": "A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU."
            }
        ], 
        "brief_summary": {
            "textblock": "A new formulation of Berinert (CSL830) is being investigated for the management of\n      hereditary angioedema (HAE). The main aim of the study is to assess the safety of a single\n      1500 IU dose of the new formulation of Berinert. This study will also look at the\n      pharmacokinetics of CSL830 relative to Berinert currently on the market."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hereditary Angioedema Types I and II", 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Angioedemas, Hereditary", 
                "Hereditary Angioedema Types I and II"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects without clinically significant medical conditions or laboratory\n             abnormalities\n\n          -  Male or female subjects aged 18 to 45 years inclusive, at the time of informed\n             consent\n\n          -  Non-smokers\n\n          -  Body mass index of 18.0 to 29.0 kg/m2 inclusive\n\n        Exclusion Criteria:\n\n          -  Previous history of clinically significant arterial or venous thrombosis, current\n             history of a clinically significant pro-thrombotic risk, or a clinically significant\n             abnormality on laboratory thrombotic screen at the screening visit.\n\n          -  Known or suspected hypersensitivity to the investigational medicinal product (IMP),\n             or to any excipients of the IMP.\n\n          -  Female subjects who started taking or changed dose of any hormonal contraceptive\n             regimen or hormone replacement therapy (ie, estrogen/progesterone containing\n             products) within 3 months before the screening visit.\n\n          -  Alcohol, drug, or medication abuse within one year before the study.\n\n          -  Female subjects of childbearing potential (eg, not post-menopausal) either not using,\n             or not willing to use, a medically reliable method of contraception for the entire\n             duration of the study, or have a vasectomized partner, or not sexually abstinent for\n             the entire duration of the study, or not surgically sterile.\n\n          -  Participation in another clinical study (or use of another IMP) within 30 days (or 5\n             times the half-life, whichever is longer) before, or during, the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760343", 
            "org_study_id": "CSL830_1001", 
            "secondary_id": "2012-002429-31"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Berinert, then CSL830", 
                    "CSL830, then Berinert"
                ], 
                "description": "Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.", 
                "intervention_name": "Berinert", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Berinert, then CSL830", 
                    "CSL830, then Berinert"
                ], 
                "description": "CSL830 is a formulation of Berinert.", 
                "intervention_name": "CSL830", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Complement C1 Inactivator Proteins", 
                "Complement C1 Inhibitor Protein", 
                "Complement C1", 
                "Complement C1s"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany"
                }, 
                "name": "Study Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Single-center, Cross-over Study to Evaluate the Safety, Bioavailability and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor Administered Intravenously", 
        "overall_official": {
            "affiliation": "CSL Behring", 
            "last_name": "Global Clinical Program Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Paul-Ehrlich-Institut"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events (AEs) within 24 hours of CSL830 infusion", 
            "safety_issue": "Yes", 
            "time_frame": "From the start of infusion to 24 hours after the end of infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760343"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of adverse events (AEs) within 10 days of the CSL830 infusion", 
                "safety_issue": "Yes", 
                "time_frame": "From the start of infusion to 10 days after the infusion"
            }, 
            {
                "description": "Relative bioavailability in terms of maximum concentration (Cmax) of CSL830 versus Berinert", 
                "measure": "Relative bioavailability of CSL830 versus Berinert - Cmax", 
                "safety_issue": "No", 
                "time_frame": "240 hours"
            }, 
            {
                "description": "Relative bioavailability in terms of area under the curve from timepoint 0 to infinity (AUC0-\u221e) of CSL830 versus Berinert", 
                "measure": "Relative bioavailability of CSL830 versus Berinert - AUC", 
                "safety_issue": "No", 
                "time_frame": "240 hours"
            }
        ], 
        "source": "CSL Behring", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CSL Behring", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}